Review

Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart

Gregory Aubert, Rick B. Vega, Daniel P. Kelly

Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA

A R T I C L E   I N F O

Article history:
Received 27 June 2012
Received in revised form 21 August 2012
Accepted 24 August 2012
Available online 31 August 2012

Keywords:
Heart failure
Mitochondria
Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α)
Fatty acid oxidation (FAO)

A B S T R A C T

The heart is an omnivore organ that requires constant energy production to match its functional demands. In the adult heart, adenosine-5′-triphosphate (ATP) production occurs mainly through mitochondrial fatty acid and glucose oxidation. The heart must constantly adapt its energy production in response to changes in substrate supply and work demands across diverse physiologic and pathophysiologic conditions. The cardiac myocyte maintains a high level of mitochondrial ATP production through a complex transcriptional regulatory network that is orchestrated by the members of the peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family. There is increasing evidence that during the development of cardiac hypertrophy and in the failing heart, the activity of this network, including PGC-1, is altered. This review summarizes our current understanding of the perturbations in the gene regulatory pathways that occur during the development of heart failure. An appreciation of the role this regulatory circuitry serves in the regulation of cardiac energy metabolism may unveil novel therapeutic targets aimed at the metabolic disturbances that presage heart failure. This article is part of a Special Issue entitled: Cardiomyocyte Biology: Cardiac Pathways of Differentiation, Metabolism and Contraction.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

To meet the workload demands of a constant pump, the mammalian heart requires an incredibly high capacity for energy production. The ability of the heart to store energy, however, is limited. Therefore, the capacity to produce ATP in the heart must be tightly matched with work demands and fuel delivery. Much of this regulation occurs through a complex network of transcription factors that respond to changes in substrate (fatty acids and glucose) delivery, oxygen availability, and a myriad of physiological conditions.

The mitochondrion serves as the principal energy-producing organelle in the heart and accounts for up to 40% of the cardiac myocyte volume. Under normal conditions, 60–80% of ATP production in the heart is derived from mitochondrial fatty acid β-oxidation. The remainder is from carbohydrate (glucose and lactate) and to a lesser degree, ketone body oxidation. However, the heart is extremely metabolically flexible, capable of changing fuel source depending on substrate availability or hormonal milieu (e.g. insulin levels). Structural changes of the heart including physiological and pathological forms of cardiac hypertrophic growth are also associated with changes in fuel selection and energy-producing capacity. In the setting of heart failure, perturbations in cardiac energy metabolism have numerous consequences including a reduction in capacity and efficiency of mitochondrial respiration and ATP production. It is now recognized that the failing heart is “energy starved”. This review focuses on the gene regulatory pathways controlling mitochondrial energy production in the cardiac myocyte with an emphasis on the dysregulation that occurs during development of heart failure.

2. Changes in mitochondrial energy transduction and ATP generation

2.1. Energy production

The concept of the “energy starved” failing heart has been extensively reviewed elsewhere [1] and will not be addressed in detail here. It is well known that levels of the main storage buffer for ATP, phosphocreatine (PCr), fall during the development of pathologic cardiac hypertrophy and during the progression to heart failure. Phosphocreatine serves as a shuttle molecule to deliver high-energy phosphate from ATP produced in the mitochondria to ATP consumed at the myofibrillar structure. The PCr:ATP ratio has been shown to be a powerful predictor of mortality in patients with dilated cardiomyopathy [2]. A lower total [PCr] in the cell may reflect reduced mitochondrial respiration and ATP flux. When the [PCr] falls, ADP, AMP and Pi concentrations rise and activate glycolytic pathways through increased glucose transport and utilization. Although initially increased to meet the deficiency in energy production, the increased glycolytic
rate is insufficient to meet the energy demands of the failing heart. It is now recognized that the energetic remodeling in the failing human heart leads to an approximate 30% decrease in [ATP] [2]. Of particular interest are the signaling events and mechanisms that lead to decreased energy production in the failing heart as well as potential therapeutic strategies to improve the energy starved heart.

2.2. Energy transduction pathways

There have been a number of studies aimed at assessing the expression of the components of energy-producing pathways in the failing heart [3,4]. Similar to the expression of many structural and contractile proteins, there is a switch to the “fetal gene program” evident in metabolic enzyme gene expression in cardiac hypertrophy and failure [5]. Among the most evident changes is a decrease in the expression of genes encoding fatty acid β-oxidation enzymes that begins during the development of cardiac hypertrophy. The rates of FAO have also been shown to be lower in experimental and human heart failure [6,7]. Coordinate changes in FAO enzyme levels have now been confirmed by a number of studies using proteomic approaches to measure changes in mitochondrial protein expression. For example, a recent mitochondrial comparative proteomic study in a rat pressure-overload model revealed downregulation of multiple FAO enzymes [7]. This was associated with increased expression of glucose oxidation enzymes in the mitochondria. Interestingly, upregulation of cardiac mitochondrial FAO enzyme expression has been observed in a number of diabetic models consistent with an activation of fatty acid oxidation rates [8–10]. This likely reflects the high influx of free fatty acids and activating ligands for this pathway (discussed more below). Cardiac hypertrophy and failure are also associated with changes in multiple components of the electron transport chain (ETC). However, even within the same model and study, divergent responses in different ETC components have been observed, underscoring the complex regulatory network that controls cardiac mitochondrial energy production [7,11].

Interestingly, exercise training can produce cardiac hypertrophy that is not characterized by the classic pathologic fetal gene signature or dysfunction [12]. This so-called “physiologic hypertrophy” is accompanied by increases in capacity for mitochondrial respiration and ATP synthesis [13]. In addition, some studies have also demonstrated an increase in FAO rates and enzyme expression in physiological forms of cardiac hypertrophy [14,15]. These observations raise the possibility that the metabolic effects of exercise training may be of some benefit in the setting of heart failure. Indeed, both animal and clinical studies have demonstrated a benefit from exercise training in both cardiac function and quality of life [16,17].

Finally, advances in clinical imaging have enabled measurements of myocardial glucose and fatty acid metabolism in humans with heart failure. The use of positron emission tomography (PET) with 11C-palmitate has demonstrated that a decrease in myocardial FAO is an independent predictor of left ventricular hypertrophy (LVH) in hypertension [18]. Furthermore, LVH is associated with a decrease in both fatty acid metabolism and myocardial efficiency [19]. These studies correlate well with the molecular changes that have been observed in FAO enzyme expression during cardiac hypertrophy.

3. Nuclear receptors: key transcriptional regulators of cardiac fuel and energy metabolism

A network of transcription factors respond to changes in substrate availability, as well as growth and stress stimuli, to ensure that the capacity for fuel burning keeps up with demands. Changes in the levels and activities of these factors play a key role in the perturbations in energy production pathways known to occur during the development of heart failure. In addition, nuclear receptors, as ligand-activated proteins (discussed further below), have been actively pursued as therapeutic targets for metabolic and cardiovascular disease. The nuclear receptor family of transcription factors is now known to regulate virtually all aspects of cardiac mitochondrial energy production.

3.1. Peroxisome proliferator-activated receptors (PPARs)

Peroxisome proliferator-activated receptors (PPARs) are members of the extended nuclear hormone receptor family [20,21]. All 3 isoforms, PPARα, PPARγ/δ, and PPARγ, heterodimerize with the retinoid X receptor (RXR) and bind a specific DNA sequence or PPAR response element (PPRE) to activate transcription. PPARα is highly expressed in the myocardium and participates in the regulation of fatty acid transport and mitochondrial and peroxisomal fatty acid oxidation pathways [22]. PPARα is able to respond to changes in substrate availability through its ligand binding domain. Recent studies relevant to the liver suggest that long-chain fatty acids and phospholipids can serve as endogenous ligands [23]. In the heart, a recent study suggests that adipose triglyceride lipase (ATGL) generates biologically active lipid species that serve as PPARα activating ligands [24]. In support of this, ATGL knockout mice display a profound reduction of cardiac FAO gene expression along with multiple mitochondrial derangements. This finding unveils a potential mechanism in matching cardiac myocyte fatty acid storage and utilization.

The activity of PPARα signaling has been implicated in the known and divergent substrate shifts in different pathophysiological scenarios known to lead to heart failure (Fig. 1). Fatty acid utilization is known to be downregulated coincident with an increase in glucose utilization in pressure overload-induced cardiac hypertrophy. In the insulin resistant and diabetic heart the opposite substrate shifts occur (Fig. 1). The roles of PPARα in controlling cardiac fuel metabolism in health and disease have been defined, in part, by genetically engineered gain-of-function and loss-of-function mouse models. Mice that overexpress PPARα exclusively in the heart (MHC–PPARα) exhibit increased fatty acid oxidation associated with a decrease in glucose utilization resulting in an accumulation of triglyceride and a diabetic-like phenotype [25,26]. These animals exhibit left ventricular hypertrophy and cardiac dysfunction that can be inhibited by deletion of CD36, a cellular fatty acid import protein [27,28]. High circulating levels of free fatty acids present in obesity and metabolic disease may activate cardiac PPARα and contribute to the observed high FAO rates in this condition (see Fig. 2). In addition, several groups have also reported an induction of PPARα levels in the diabetic mouse heart [29–31]. In contrast, mice lacking PPARα demonstrate a decrease in fatty acid oxidation and increased glucose utilization [32–34]. Interestingly, and in contradistinction to the diabetic heart, PPARα expression is decreased in human and animal models of pressure overload-induced cardiac hypertrophy and in heart failure [5,35–37]. This is in agreement with the observed metabolic shift from fatty acid oxidation to glucose metabolism that occurs during the transition to cardiac hypertrophy and heart failure [38–40].

PPARγ/δ regulates expression of a set of overlapping targets with PPARα including FAO enzymes. However, in contrast to PPARα, PPARγ/δ also activates glucose utilization in the heart [41]. Mice expressing PPARγ/δ in the heart are also relatively resistant to diet-induced cardiac myocyte lipid accumulation and lipotoxic cardiomyopathy. Consistent with these observations, cardiac-specific deletion of the PPARγ/δ gene in mice results in a decrease in fatty acid and glucose oxidation rates concomitant with a decrease in the expression of genes in both pathways [42].

The role of cardiac PPARγ is less well understood. Although it is expressed at much lower levels in the heart compared to either PPARα or PPARγ/δ, deleterious effects of cardiac PPARγ-deficiency in mice have been reported by independent groups [43,44]. Cardiac overexpression of PPARγ also leads to cardiac dysfunction with lipid accumulation and mitochondrial abnormalities [45]. Therefore,
it would seem that a critical balance in the level of PPARγ activity is necessary for proper cardiac function.

3.2. Estrogen-related receptor (ERR)

Also belonging to the nuclear receptor superfamily, the estrogen-related receptor (ERR) family is composed of three members, ERRα, ERRβ and ERRγ [46–48]. Endogenous ligands for ERRs have not been identified and crystallography studies suggest that the ligand-binding pocket of ERRα may be too small for any to exist [49]. ERRα and ERRγ are enriched in tissues with high oxidative metabolic rates such as the heart.

ERRα controls the expression of many genes involved in energy metabolism pathways including cellular fatty acid transport, mitochondrial and peroxisomal fatty acid oxidation and mitochondrial respiration [50]. ERRα also activates expression of PPARα providing an additional layer of cross-regulation [50]. Genome-wide association studies have determined that ERRα and ERRγ likely act as nonobligatory heterodimers and target a common set of promoters [51]. ERRα is required for the adaptive response to hemodynamic stress as loss-of-function results in decompensated heart failure when mice are subjected to left ventricular pressure overload. This is associated with myocardial phosphocreatine depletion and reduced maximal ATP synthesis [52]. Furthermore, expression of ERR target genes including those involved in glucose metabolism, FAO and the ETC are significantly downregulated in human heart failure samples suggesting that interruption of normal ERR function contributes to the pathophysiology of heart failure.

A critical role for ERRγ in the control of cardiac energy metabolism has also been demonstrated in loss-of-function studies. ERRγ knockout mice display a downregulation of several ERR targets in the heart, exhibit cardiomyopathy, and die immediately following birth. The early postnatal death in these animals probably results from the inability to transition from glucose to fatty acid utilization following birth [53].

4. PPARγ coactivator-1 (PGC-1)

The discovery of peroxisome proliferator-activated receptor (PPAR)γ coactivator-1α (PGC-1α) provided the first clue as to how the complex transcriptional regulatory circuit controlling cardiac metabolism was orchestrated in accordance with energy demands. PGC-1α was first cloned in brown adipose tissue as a PPARγ interacting protein [54]. The PGC-1 family also contains two other members, PGC-1β and PGC-1-related coactivator (PRC) [55,56]. PGC-1α is an inducible transcriptional coregulator activated by
stimuli that increase demands of mitochondrial flux such as cold exposure and exercise [57–59]. PGC-1α expression in the heart is induced during heart development concomitant with the mitochondrial burst that occurs just before birth [60]. An increase in PGC-1α cardiac expression is also observed following acute and chronic exercise training which may be dependent, in part, upon insulin growth factor 1 (IGF1) signaling [61]. Overexpression studies confirmed that PGC-1α directly interacts and activates the targets of PPARα [62], PPARγ [62, 63], ERRα and ERRγ [64–66]. These results suggest that PGC-1 integrates physiologic signals and developmental cues to regulate virtually all aspects of mitochondrial function (Fig. 3).

Somewhat surprisingly, myocardial mitochondrial volume and ventricular function are not diminished in PGC-1α knockout animals [67, 68]. The relatively mild phenotype is related to functional redundancy between PGC-1α and PGC-1β. Indeed, disruption of both the PGC-1α and PGC-1β genes prevents perinatal mitochondrial biogenesis in the heart causing cardiomyopathy and death shortly after birth [69]. Given its critical role in mitochondrial function, a logical question is whether dysregulation of PGC-1 is involved in the pathogenesis of the “energy-starved” phenotype of the failing heart. The changes in fuel selection and mitochondrial function in the hypertrophied and failing heart are likely consequences of dysregulation of the PGC-1 circuit. Consistent with this notion, the expression of PGC-1α is downregulated in both animal models and human heart failure samples [5, 70, 71]. In addition, PGC-1α and PGC-1β deficient mice develop heart failure following pressure overload [72, 73]. Taken together, these data suggest that deactivation of PGC-1 and accompanying metabolic derangements contribute to the development of heart failure. Furthermore, the activity of PGC-1 may be altered independent of its expression by post-translational modifications including phosphorylation and acetylation. PGC-1α activity can be increased through direct phosphorylation by AMPK [74]. Further regulation of PGC-1α activity is controlled by opposing actions of GCN5 (acetylation) [75] and SIRT1 (deacetylation) [76]. Changes in intracellular energy production and nutrient availability known to occur during heart failure impact the activity of both AMPK and SIRT1. However, the role of alterations in the upstream signaling pathways and the consequence of these changes on PGC-1 activity during the development of heart failure have not been fully explored in animal models or humans.

5. Other relevant transcription factors

5.1. MEF2

The myocyte enhancer factor-2 transcription factor has been shown to regulate many growth and remodeling genes during cardiac hypertrophy [77]. A link between MEF2A and cardiac metabolism was first shown in MEF2A knockout mice which displayed decreased mitochondrial content and perinatal lethality [78]. Subsequently, MEF2 was shown to directly activate transcription of PGC-1α [79]. Cardiac MEF2 activity is tightly controlled by class II histone deacetylases including HDAC4 and HDAC5. Class II HDACs have been shown to be signal-responsive inhibitors of MEF2 and pathologic cardiac growth [80, 81]. In this context, dysregulation of MEF2 activity could contribute to perturbations in cardiac energy production during hypertrophy and failure.

5.2. NRF-1

Nuclear respiratory factor-1 (NRF-1) was originally identified through its binding of the cytochrome c promoter [82]. Subsequent characterization of its binding site demonstrated that NRF-1 regulates
the expression of different genes encoding mitochondrial electron transport chain complex subunits [83]. Moreover, NRF-1 induces the expression of the mitochondrial transcription factor A (Tfam), that plays a role in mitochondrial DNA transcription, stabilization and maintenance [84,85]. NRF-1 knockouts are embryonically lethal at day 6.5 and show impaired mitochondrial membrane potential as well as a decrease in the mitochondrial DNA content [86]. Interestingly, NRF-1 also induces MEF2 expression to coordinate expression of mitochondrial respiratory chain subunits [87]. Along with direct regulation of PGC-1α by MEF2A, this network provides a positive feedback loop through NRF-1, MEF2A, and PGC-1α to control mitochondrial function and content in the cardiac myocyte.

6. Implications for the development of new therapeutic approaches targeting cardiac energy metabolism

The rates of heart failure are rising as the population continues to age. There is a clear unmet medical need for new therapeutic approaches for this problem, particularly aimed at the early stages. Indeed, the prognosis for heart failure patients on current therapies remains dismal, with a 5-year mortality rate of around 50% [88]. In addition, a significant proportion of heart failure patients have preserved ejection fraction (HFpEF) or so-called diastolic heart failure, for which there is no evidence-based medical treatment that improves mortality in these patients [89]. The traditional emphasis on heart failure with decreased ejection fraction and lack of reliable animal models has also limited our understanding of the metabolic derangements that occur in HFpEF. There is currently no heart failure therapeutic that directly targets metabolism or energy production.

6.1. Myocardial substrate utilization

To date, the most extensively studied and cited potential therapeutic intervention, particularly in the setting of ischemia, is to decrease mitochondrial FAO and force a shift to increased glucose utilization. This shift would lead to a more oxygen efficient state in terms of ATP production. It should be noted, however, that the utility of this approach, particularly in non-ischemic scenarios remains to be proven. Several strategies have been employed in preclinical studies including targeting free fatty acid uptake, fatty acid entry into the mitochondria or direct FAO inhibition [3]. Although certain agents have now been approved for the treatment of angina, none have progressed far for the treatment of chronic heart failure.

However, some evidence suggests that partial FAO inhibitors, such as trimetazidine, have a positive effect on cardiac function and remodeling in addition to their anti-anginal activities [90]. Definitive clinical trials are needed to establish these initial findings in chronic heart failure.

Not all evidence supports the strategy to inhibit FAO. Cardiac overexpression of pyruvate dehydrogenase kinase 4 (PDK4) in transgenic mice leads to very high FAO rates and decreased glucose utilization [91]. Surprisingly, however, these mice have normal recovery following ischemia/reperfusion injury and some evidence for protecting against myocyte lipid accumulation due to a high fat diet, which would potentially be beneficial in diabetic forms of cardiac dysfunction. PGC-1α levels and target gene expression are also upregulated in these mice. These results underscore that a “one-size fits all” approach to modulating fuel utilization may not be optimal and that therapies targeting myocardial energy production will need to be tailored to the specific disease state. Moreover, strategies to increase fatty acid catabolism in heart must be matched with a corresponding increase in mitochondrial respiratory capacity. Lastly, one therapeutic approach may be well-suited for a diabetic patient with ectopic lipid accumulation and high FAO rates but ineffective or even detrimental to a patient with hypertension and a different metabolic profile.

6.2. PGC-1 as a therapeutic target to maintain or increase mitochondrial function

Given the importance of PGC-1 in the regulation of virtually all aspects of mitochondria, it is reasonable to hypothesize that strategies to increase PGC-1 levels and/or activity will increase energy production in the failing heart. However, this concept has not been definitively tested. The approach in pre-clinical models is complicated by the fact that cardiac overexpression of PGC-1α results in cardiomyopathy as a result of uncontrolled mitochondrial biogenesis [60]. To date, effective small molecule activators of PGC-1α have not been developed. However, cardiac overexpression of PGC-1α is cardioprotective in a lipopolysaccharide (LPS) challenge model [92]. Upstream modulators of PGC-1 may also serve as interventional points. Specific inhibition or activation of GCN5 and SIRT1, respectively, would be predicted to activate PGC-1. Modulation of each of these factors has been shown to increase PGC-1 activity [93,94]. Definitive studies are needed to establish the benefit of PGC-1 activation in the setting of heart failure.

Fig. 3. PGC-1α control of cardiac mitochondrial function. PGC-1α integrates signals from physiologic stimuli as well as upstream modulators such as sirtuins (SIRT) and AMPK. Direct interaction with multiple transcription factors drives expression of proteins involved in all aspects of mitochondrial function. SIRT1, sirtuin 1; AMPK, AMP-activated protein kinase; PGC-1α, PPARγ coactivator-1 alpha; PPARα, peroxisome proliferator-activated receptor alpha; RXR, retinoid X receptor; ERR, estrogen-related receptor; NRF, nuclear respiratory factor; ETC, electron transport chain; OXPHOS, oxidative phosphorylation.
6.3. Nuclear receptor activation

Ligands for specific nuclear receptors, particularly the PPARs, have been developed and, in some cases, serve to increase the interaction with PGC-1. Data with PPARx ligands in experimental heart failure models has been mixed [95]. Clinically, PPARx ligands have a very favorable safety profile; however, they have not been specifically tested in a heart failure population. Moreover, PPARx ligands would theoretically be restricted to those patients with reduced myocardial FAO. PPARx activation may actually participate in the development of lipotoxic cardiomyopathy in the setting of obesity and diabetes. In addition, the extra-cardiac effects of PPARx activation must be considered.

As discussed above, ERRs also interact with PGC-1 to drive virtually all aspects of mitochondrial biogenesis. In contrast to the PPARs, the relatively small ligand binding domain has hindered the development of ERR activating ligands. ERRy would appear to offer the best target in this regard.

6.4. Lipid storage pathways

Perturbations in lipid handling and storage in the cardiac myocyte may also impact energy production in the heart, especially in the cardiac dysfunction associated with obesity and diabetes. Mice deficient in stearoyl-CoA desaturase (SCD1), the rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids, has been shown to decrease cardiac lipid accumulation and improve cardiac function on the leptin-deficient ob/ob background [96]. Loss of SCD1 also decreased PPARα levels and β-oxidation rates observed in ob/ob mice. Clinical development of SCD1 inhibitors, however, has been problematic due to unwanted side effects. Similar effects have been observed with the deletion of diacylglycerol acyltransferase 1 (DGAT1), which catalyzes the final step in triglyceride synthesis. Cardiac triglyceride accumulation is reduced and increases in PPARα, β-oxidation, and fatty acid import genes are inhibited when DGAT1 knockout mice are placed on a high-fat diet [97]. A remaining question is the fate of the unstored fatty acids in the absence of DGAT1 activity. However, at least one study suggests that these are shuttled to the mitochondrial β-oxidation pathway [98]. Taken together, these data suggest that inhibition of cardiac lipid accumulation could serve as a promising therapeutic target in the development of lipotoxic cardiomyopathy.

7. Concluding remarks

The healthy heart has an amazing capacity to shift substrate utilization preferences in response to pathophysiologic stimuli to meet its energy needs. This fuel utilization flexibility becomes constrained during the development of heart failure. In addition to changes in structural and contractile proteins, myocardial energy metabolism is remodeled during cardiac hypertrophy and failure. Importantly, different forms of cardiac disease, such as hypertension/ischemia versus obesity/diabetes are characterized by distinct and directionally different alterations in cardiac fuel metabolism. These changes are driven, in part, by a complex transcriptional regulatory network that responds to numerous inputs including nutrient availability and increased workload. There is a prime opportunity and medical need to develop therapeutics that directly address the underlying metabolic derangements that occur early during the development of heart failure. This could, in essence, lead to a more precise or personalized approach to this problem, and at an early stage. In the long-term, such therapies could, perhaps, be tailored to the etiology of heart failure and the accompanying metabolic derangements.

Disclosures

D.P.K. serves on Scientific Advisory Boards for Johnson & Johnson, Pfizer, and Eli Lilly & Company.

Acknowledgements

This work was supported by NIH grants (RO1 DK045416, RO1 HL058493, RO1 HL110189 [D.P.K.]) and The Swiss National Science Foundation (PBLAP3 136880 [GA]). We thank Lorenzo Thomas for the help in manuscript preparation and Teresa Leone for the critical reading of the manuscript.

References


Disclosures

D.P.K. serves on Scientific Advisory Boards for Johnson & Johnson, Pfizer, and Eli Lilly & Company.

Acknowledgements

This work was supported by NIH grants (RO1 DK045416, RO1 HL058493, RO1 HL110189 [D.P.K.]) and The Swiss National Science Foundation (PBLAP3 136880 [GA]). We thank Lorenzo Thomas for the help in manuscript preparation and Teresa Leone for the critical reading of the manuscript.


J.M. Huss, R.P. Kopf, D.P. Kelly, Peroxisome proliferator-activated receptor coactivator alpha (PGC-1 alpha) coactivates the cardiac-enriched nuclear...


